Role of leukemia inhibitory factor and its receptor in mouse primordial germ cell growth

Linzhao Cheng¹, David P. Gearing²,*, Lynn S. White³, Debra L. Compton¹, Ken Schooley² and Peter J. Donovan¹,†

¹Cell Biology of Development and Differentiation Group, ABL-Basic Research Program, NCI-FCRDC, PO Box B, Frederick, Maryland 21702-1201, USA
²Immunex Research and Development Corporation, 51 University Street, Seattle, WA 98101, USA
³PRI/Dyncorp, NCI-FCRDC, PO Box B, Frederick, MD 21702-1201, USA

*Current address: Systemix, Inc. 3155 Porter Drive, Palo Alto, CA 94404, USA
†Author for correspondence

SUMMARY

The pleiotropic cytokine leukemia inhibitory factor (LIF) is able to promote the growth of mouse primordial germ cells (PGCs) in culture. It is unclear whether LIF acts directly on PGCs or indirectly via feeder cells or embryonic somatic cells. To understand the role of LIF in PGC growth, we have carried out molecular and cell culture analyses to investigate the role of both the LIF ligand and its receptor in PGC development. LIF is able to stimulate PGC growth independently of the presence of feeder cells supporting the hypothesis that LIF acts directly on PGCs to promote their growth. We show here that transcripts for the low-affinity LIF receptor (LIFR), an integral component of the functional LIF receptor complex, are expressed in the developing gonad. Fluorescence-activated cell sorter (FACS) analysis, using an anti-LIFR antiserum, demonstrates that LIFR is present on the surface of PGCs, suggesting that PGCs are likely to be a direct target of LIF action in culture. Signalling via LIFR is essential for PGC growth in culture since the anti-LIFR antiserum, which blocks LIF binding to its receptor, abolishes PGC survival in culture. Two LIF-related cytokines, namely oncostatin M and ciliary neurotrophic factor, can also promote PGC growth in culture in addition to LIF. Thus one or more of these LIFR-dependent cytokines may play an important role in PGC development in mice.

Key words: primordial germ cells (PGCs), leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF), interleukin-6 (IL-6), basic fibroblast growth factor (bFGF), steel factor (SLF), c-kit receptor tyrosine kinase, LIF receptor (LIFR), embryonic stem (ES) cells, embryonic germ (EG) cells

INTRODUCTION

Primordial germ cells (PGCs) are the embryonic precursors of the sperm and ova of adult animals (recently reviewed by McLaren, 1992; Wylie, 1993). Mouse PGCs are first identified in the embryo at 7.0 days post coitus (dpc) as a small population of cells expressing alkaline phosphatase (AP) (EC.3.1.3.1) (Ginsburg et al., 1990). During the subsequent 5 to 6 days of development, they migrate to the gonad anlagen and proliferate rapidly to establish a population of approximately 25,000 germ cells (Tam and Snow, 1981). Shortly after arrival in the gonad, at around 13.5 dpc, PGCs stop mitotic cell division and enter mitotic arrest in the developing testis or meiosis in the ovary. Despite the importance of PGCs to the survival of animal species, until recently very little was known about the growth factors regulating PGC proliferation and differentiation. A major advance in our understanding of PGC growth control came with the characterization of two sterile mouse mutants, Dominant White Spotting (W) and Steel (Sl). These two loci encode a tyrosine kinase receptor (c-kit) and its cognate ligand, Steel factor (SLF), respectively (reviewed by Witte, 1990). The c-kit receptor is expressed by PGCs while SLF is expressed by surrounding somatic cells and by the feeder cells used for culturing PGCs in vitro (Matsui et al., 1990; Dolci et al., 1991; Godin et al., 1991). We and others have demonstrated that SLF is essential for PGC survival in vitro as it is in vivo (Dolci et al., 1991; Godin et al., 1991; Matsui et al., 1991).

Although SLF is required for PGC survival in culture, PGC proliferation is not tightly correlated with the amount of SLF produced by feeder cells. Certain feeder cells such as STO embryonic fibroblasts produce additional diffusible factors that, together with SLF, stimulate PGC proliferation (Dolci et al., 1991). One such factor is leukemia inhibitory factor (LIF) (Matsui et al., 1991). Even though STO cells produce LIF, addition of exogenous, recombinant LIF is able to promote further the growth of PGCs cultured on STO feeder cells (Resnick et al., 1992; Matsui et al., 1992). In the presence of a third factor, basic fibroblast growth factor (bFGF), SLF and...
LIF promote long-term proliferation of PGCs in culture. The resultant cell lines, which we have termed embryonic germ cells, or EG cells, resemble undifferentiated embryonic stem (ES) cells (Resnick et al., 1992; Matsui et al., 1992; Stewart et al., 1994).

LIF is a cytokine consisting of about 200 amino acids that can act in different ways on a variety of different cell types (Gearing et al., 1987; Gough et al., 1988). LIF was first discovered by virtue of its ability to inhibit proliferation of M1 mouse monocytic leukemic cells and to induce them to differentiate into macrophages (Hilton et al., 1988a,b; Metcalf et al., 1988). LIF was also identified as a differentiation inhibitory activity (DIA) that is able to prevent ES cells from differentiating and therefore to maintain them in an undifferentiated state (Smith et al., 1988; Williams et al., 1988). In addition, LIF stimulates proliferation of cultured DA-1a mouse myeloid cells (Moreau et al., 1988). In synergy with interleukin 3, LIF can augment the proliferation of human hematopoietic progenitors and potentiate megakaryocyte production in culture (Leary et al., 1990; Metcalf et al., 1991). Based on analyses of protein secondary structure and genomic organization, LIF has been placed in an emerging family of cytokines which includes interleukin-6 (IL-6), oncostatin M (OSM) and ciliary neurotrophic factor (CNTF) and with which LIF shares some overlapping biological activity (Rose and Bruce, 1991; Bazan, 1991). Our understanding of the pleiotropic functions of LIF was advanced by the molecular characterization of the cell surface receptor for LIF. The LIF receptor comprises a low-affinity, LIF-binding subunit (referred to here as LIFR) and a second transmembrane molecule, gp130, which was originally identified as the IL-6 signal transducer (Gearing et al., 1991, 1992). Activation of the LIF receptor complex requires heterodimerization of LIFR and gp130, and is accompanied by tyrosine phosphorylation of both subunits (Ip et al., 1992; Taga and Kishimoto, 1992; Davis et al., 1993). As members of the emerging cytokine receptor family, these two related transmembrane proteins serve as components of bipartite or tripartite receptors for multiple cytokines. For example, the LIFR/gp130 complex also functions as a high affinity receptor for OSM (Gearing et al., 1992). Addition of a third component, the low affinity receptor for CNTF (CNTFRez), converts the bipartite LIFR/gp130 complex into a tripartite, high-affinity receptor for CNTF (Ip et al., 1992; Davis et al., 1993; Baumann et al., 1993). Thus, both LIFR and gp130 are required for the signal transduction of multiple cytokines including LIF, OSM and CNTF. That the same heterodimeric receptor complex is used in the signal transduction for LIF, OSM and CNTF may in part explain the pleiotropic and overlapping functions of these related cytokines.

Because LIF can act on a wide variety of cells types, interpretation of its role in PGC culture assays is complicated. LIF could act directly on PGCs or it could stimulate feeder cells or embryonic somatic cells to produce growth-promoting factors for PGCs. It is also not clear how LIF acts to stimulate PGC growth, although several models have been postulated. LIF could act as a survival factor, a mitogen, or as a differentiation inhibiting activity (De Felici and Dolci, 1991; Matsui et al., 1991; Resnick et al., 1992; Pesce et al., 1993). To understand the role of LIF in PGC growth, we have carried out a series of experiments examining the action of both LIF and its receptor. We report here that the LIFR is present on the surface of PGCs and is essential for PGC growth in culture. The stimulation of PGC proliferation by LIF is not alleviated by the presence of SLF and bFGF, and is independent of feeder cells, indicating that LIF has a distinct and direct function in supporting PGC growth. Two LIF-related cytokines, OSM and CNTF can also promote PGC growth in culture. The potential functions of these LIFR-dependent cytokines in PGC growth and development will be discussed.

**MATERIALS AND METHODS**

**PGC isolation and culture**

PGC isolation and culture were performed as described previously. Briefly, single cell suspensions of dissected genital ridges from 11.5 dpc B6C3F1 mouse embryos were prepared by trypsin digestion and cultured in 96-well microtiter plates as previously described (Dolci et al., 1991). PGCs were maintained in 200 µl DMEM (high glucose) supplemented with 15% FCS, L-glutamine, sodium pyruvate, non-essential amino acids (N-2) and 50 units/ml penicillin streptomycin. To determine whether LIF can act directly on PGCs or it could stimulate feeder cells or embryonic somatic cells to produce growth-promoting factors for PGCs, we have carried out a series of experiments examining the action of both LIF and its receptor on PGCs. LIF was identified as the IL-6 signal transducer (Gearing et al., 1990). Our understanding of the pleiotropic functions of LIF was advanced by the molecular characterization of the cell surface receptor for LIF. The LIF receptor comprises a low-affinity, LIF-binding subunit (referred to here as LIFR) and a second transmembrane molecule, gp130, which was originally identified as the IL-6 signal transducer (Gearing et al., 1991, 1992). Activation of the LIF receptor complex requires heterodimerization of LIFR and gp130, and is accompanied by tyrosine phosphorylation of both subunits (Ip et al., 1992; Taga and Kishimoto, 1992; Davis et al., 1993). As members of the emerging cytokine receptor family, these two related transmembrane proteins serve as components of bipartite or tripartite receptors for multiple cytokines. For example, the LIFR/gp130 complex also functions as a high affinity receptor for OSM (Gearing et al., 1992). Addition of a third component, the low affinity receptor for CNTF (CNTFRez), converts the bipartite LIFR/gp130 complex into a tripartite, high-affinity receptor for CNTF (Ip et al., 1992; Davis et al., 1993; Baumann et al., 1993). Thus, both LIFR and gp130 are required for the signal transduction of multiple cytokines including LIF, OSM and CNTF. That the same heterodimeric receptor complex is used in the signal transduction for LIF, OSM and CNTF may in part explain the pleiotropic and overlapping functions of these related cytokines.

Because LIF can act on a wide variety of cells types, interpretation of its role in PGC culture assays is complicated. LIF could act directly on PGCs or it could stimulate feeder cells or embryonic somatic cells to produce growth-promoting factors for PGCs. It is also not clear how LIF acts to stimulate PGC growth, although several models have been postulated. LIF could act as a survival factor, a mitogen, or as a differentiation inhibiting activity (De Felici and Dolci, 1991; Matsui et al., 1991; Resnick et al., 1992; Pesce et al., 1993). To understand the role of LIF in PGC growth, we have carried out a series of experiments examining the action of both LIF and its receptor. We report here that the LIFR is present on the surface of PGCs and is essential for PGC growth in culture. The stimulation of PGC proliferation by LIF is not alleviated by the presence of SLF and bFGF, and is independent of feeder cells, indicating that LIF has a distinct and direct function in supporting PGC growth. Two LIF-related cytokines, OSM and CNTF can also promote PGC growth in culture. The potential functions of these LIFR-dependent cytokines in PGC growth and development will be discussed.

**Growth factors and neutralizing antibodies**

Recombinant murine SLF (a soluble form of SLF) made in yeast was a generous gift of Dr D. E. Williams (Immunex). Recombinant human bFGF, murine LIF (ESGRO) and a neutralizing monoclonal IgG (ACK-2) against the c-kit receptor (Nishikawa et al., 1991) were purchased from GIBCO/BRL. Recombinant human OSM, rat CNTF, murine IL-6 and a purified rat monoclonal IgG against murine IL-6R (Vink et al., 1990) were purchased from Genzyme. An anti-serum against the murine LIFR was raised by immunizing rabbits with a purified, recombinant protein containing the murine LIFR extracellular domain. The anti-LIFR serum was selected by its ability to block LIF binding to both the low- and high-affinity LIFR receptors and to block LIF-induced proliferation of DA-la myeloid cells (Gearing, unpublished data).

**Biological assays for measuring the specific activity of cytokines**

The specific activities of recombinant LIF, OSM, CNTF and IL-6 were assessed by their effects on M1 cell proliferation and D3 ES cell differentiation, and normalized to that of LIF. M1 murine monocytic leukemic cells were maintained in RPMI-1640 medium plus 10% FCS. Addition of either LIF, OSM or IL-6 inhibits proliferation of M1 cells monitored by [3H]thymidine incorporation into chromosomal DNA (Metcalf et al., 1988; Rose and Bruce, 1991). The concentration of murine LIF required for achieving the half maximal activity (ED50 or 50 units/ml) of growth inhibition towards M1 cells was determined as 0.5 ng/ml, which is consistent with the specific activity (100 units/ng) determined by the supplier (GIBCO/BRL). Using the same M1 cell assay, the specific activities of recombinant human OSM and murine IL-6 were measured as 40 units/ng and 100 units/ng respectively. The activity of the monoclonal antibody (mAb) against murine IL-6Rα was also tested in the M1 cell assay. At 10 µg/ml the antibody completely blocked growth arrest and differentiation of M1 cells by IL-6 (250 units/ml) but had no effect on M1 cell growth inhibition induced by LIF or OSM.

CNTF by itself is inactive towards M1 cells (Davis et al., 1993), but it is able to substitute for LIF in maintaining D3 ES cells in an un-differentiated state (see below). D3 ES cells (obtained from the American Type Culture Collection) were maintained in an undifferentiated state on gelatin-coated dishes in DMEM (high glucose) supplemented with 15% FCS, L-glutamine, sodium pyruvate, non-
essential amino acids, β-mercaptoethanol and 1000 units/ml of LIF. Withdrawal of LIF results in ES cell differentiation accompanied by loss of alkaline phosphatase activity (Smith et al., 1988; Williams et al., 1988; Pease et al., 1990). The effects of OSM, CNTF and IL-6 were assayed by their ability to maintain AP activity of D3 ES cells. We have developed a quantitative assay to monitor the growth of undifferentiated ES cells based on their AP activity using a chromogenic substrate p-nitrophenyl phosphate (Cheng and Donovan, unpublished data). Using this assay, the ED50 of LIF (ESGRO) for D3 cell growth is measured as 1 ng/ml (or 100 units/ml). In addition to LIF, both OSM and CNTF are able to maintain the growth of undifferentiated D3 ES cells with specific activities of 40 units/ng and 20 units/ng respectively, based on a comparison with LIF. IL-6 is unable to inhibit D3 ES cell differentiation. Similar observations on the effects of OSM, CNTF and IL-6 on ES cell differentiation have been reported recently (Conover et al., 1993; Yoshida et al., 1994; Wolf et al., 1994). The amounts of recombinant cytokines used in PGC culture assays were, therefore, based on their specific activities rather than their total protein concentration.

Characterization of the anti-LIFR serum

Protein lysates from M1 cells were used for determining the specificity of the anti-LIFR antisera. Following a published protocol used in the demonstration of LIF-induced LIFR phosphorylation (Ip et al., 1992), 5×10^6 M1 cells were treated with 50 ng/ml LIF or IL-6 at 37°C for 5 minutes and lysed in 0.5 ml of Tris-buffered saline plus 1% NP-40. The soluble proteins were then incubated either with the anti-LIFR rabbit serum (1:10 dilution) or with (5 μg of) an anti-phosphorytosine mAb 4G10 (Upstate Biotechnology, Inc.). After precipitation with protein A-sepharose beads (Pharmacia), the precipitated proteins were separated by SDS-PAGE and then transferred onto a PVDF nylon membrane (Millipore) by electroblotting. The membrane was first probed with another anti-phosphorytosine mAb (PY20, Signal Transduction Inc.) conjugated to horseradish peroxidase (HRP). After stripping, the filter was reprobed with the anti-LIFR serum at 1:2,000 dilution followed by a secondary anti-rabbit antibody conjugated to HRP (Boehringer Mannheim Biologicals). An ECL detection system (Amer sham) was used to detect bound HRP immunocomplexes.

Fluorescence-activated cell sorting (FACS) analysis

A single-cell suspension from genital ridges of 12.5 dpc mice was incubated with a mouse mAb, TG-1, which recognizes a PGC surface marker, the SSEA-1 antigen (1:10 dilution of the hybridoma culture supernatant), or an isotype-matched mouse IgM (20 μg/ml). Each cell suspension was also labelled with the anti-LIFR antisera or a normal rabbit serum (NRS) control both at 1:10 dilution for 30 minutes on ice. After extensive washing with PBS, a mixture of two fluororochrome-conjugated goat IgGs (anti-mouse IgM-fluorescein isothiocyanate [FITC] and anti-rabbit IgG-phycocerythrin [PE], both from Sigma) was added to each cell suspension and incubated for 30 minutes on ice. The samples were then washed extensively in cold PBS. Two-color FACS analysis was performed using an EPICS profile analyzer instrument (Couler corporation). The two control antibodies were used to set up arbitrary gates to separate positive cells from cells with background levels of fluorescence.

RNA protection assays for detecting LIFR transcripts

A genomic DNA fragment containing the cytoplasmic portion of the mouse LIFR was cloned by homology to the human LIFR (Gearing, unpublished data). A LIFR probe was constructed by cloning a 480 base pair (bp) segment from the mouse LIFR genomic DNA fragment (XbaI to BamHI) into the corresponding sites in the Bluescript SK+ vector (Stratagene). The anti-sense RNA probe (520 bp) for the LIFR was synthesized in the presence of [α-32P]CTP by T7 RNA polymerase using the manufacturer’s protocol (Stratagene). RNA was isolated from 11.5 dpc genital ridges, STO cells, D3 ES cells and EG cells derived from PGCs of 8.5 dpc embryos with RNAzol-B (Tel-Test, Inc.) by the method of Chomczynski and Sacchi (1987) using the manufacturer’s protocol. After hybridizing overnight with 10 μg of total RNA or transfer RNA (Sigma), the un-hybridized probe was trimmed with RNases A and T1. A β-actin probe (139 bp) was also used in each hybridization reaction as an internal control. The RNase-resistant RNAs (radioactive) were separated by size in a 6% acrylamide-urea sequencing gel. The protected β-actin fragment is 114 bp long and the protected fragment for the mouse LIFR mRNA is 310 bp long. This portion of the LIFR transcript corresponds to the cytoplasmic region from amino acids 890 to 993 numbered according to the published human sequence (Gearing et al., 1991).

RESULTS

Effect of growth factors on 11.5 dpc PGC growth in culture

The stimulatory effects of SLF, LIF, and bFGF or combinations of these factors on the growth of PGCs at both premigration and postmigration stages were examined. This report is focused on the stimulation of postmigratory PGCs, since the stimulatory effects of these growth factors on premitigatory PGCs have been published previously (Resnick et al., 1992; Matsui et al., 1992). Postmigratory PGCs were isolated from embryos of 11.5 dpc at which time approximately 70% of PGCs have reached the genital ridges (McCoeshen and McCallion, 1975; Tam and Snow, 1981). In these short-term growth assays, PGCs were cultured on a monolayer of mitotically inactive STO fibroblast cells. After a fixed period of time in culture, either in the presence or absence of various growth factors, the numbers of PGCs were determined by virtue of their AP activity. Soluble SLF slightly increased the PGC number at day 1 and day 2 of the culture period (data not shown). Recombinant LIF moderately increased the number of 11.5 dpc PGCs cultured on STO feeder cells even though the STO feeder cells produce a certain amount of LIF (Fig. 1A). bFGF by itself is also able to stimulate PGC proliferation on STO cells to a greater extent than either exogenous LIF or SLF. The stimulation of PGC growth by LIF is also observed in the presence of bFGF and the stimulatory effects of LIF and bFGF are additive. The number of PGCs increased more than two fold in 2 days if both LIF and bFGF were added.

We further tested the effect of LIF in feeder-independent cultures established from 11.5 dpc genital ridges. In these cultures, PGCs together with embryonic somatic cells are plated onto gelatin-coated substrata (Godin et al., 1991; Matsui et al., 1991). In the presence of soluble SLF, PGC numbers increased during the first 24 hours of culture and then began to decline (data not shown), consistent with previous reports (Matsu i et al., 1991). Addition of LIF partially prevented the decline of PGC numbers over a 48 hour period (Fig. 1B). The stimulatory effect of LIF on PGC growth observed in these feeder-independent cultures was greater than that observed when PGCs were cultured on STO cells. The enhancement of PGC survival by LIF was further enhanced by the addition of bFGF, in a manner similar to its effect on PGC growth on STO cells (see Fig. 1A). Therefore, the action of LIF and bFGF on PGCs are not dependent on the presence of STO feeder cells. These data suggest that LIF (and bFGF) might act directly on PGCs to promote their survival and growth in culture. These results also illustrate that stimulation of PGC growth by LIF is
not restricted to a specific stage of PGCs during development since it promoted the growth in culture of both premigratory and postmigratory PGCs (Resnick et al., 1992; Matsui et al., 1992; and this data). LIF has a distinct function in regulating PGC growth which is independent of SLF and bFGF.

**LIFR is expressed in the genital ridge**

To elucidate the function of LIF in PGC growth in vivo, we first need to know whether the bipartite, high-affinity LIF receptor, consisting of LIFR and gp130, is expressed in the developing gonad. Since gp130 is reported to be ubiquitously expressed in all murine tissues and cells examined (Saito et al., 1992), we decided to focus first on the expression of the LIFR, the LIF-binding subunit of the bipartite receptor for LIF. After the initial cloning of a murine LIFR cDNA encoding a secreted protein lacking transmembrane and cytoplasmic domains (Gearing et al., 1991), a genomic fragment containing the murine LIFR cytoplasmic domain was obtained (Gearing, unpublished data). Using this DNA fragment as a probe, we examined the expression of the LIFR in the developing gonad by RNase protection analysis (Fig. 2). In RNA samples isolated from genital ridges and several cell lines, a protected fragment of the correct size was observed while transfer RNA did not yield any signal. As expected, mouse ES cells express the LIFR since LIF can act on ES cells to inhibit their differentiation. The LIFR transcript is detected in genital ridges of 11.5 dpc mouse embryos as well as in EG cells derived from PGCs. LIFR is also expressed in STO cells. At present, it is unclear whether the LIFR in STO cells is important for their own growth or for supporting PGCs cultured on STO feeder cells. Since the effects of LIF are greater in the absence of STO cells, this suggests that the potential action of LIF on STO cells is not crucial for PGC proliferation.

**PGCs make LIFR proteins on their cell surface**

To determine further whether PGCs per se in genital ridges express a LIFR, we made use of an antiserum raised in rabbits against a recombinant murine LIFR protein. This anti-LIFR serum was shown to block the binding of LIF to COS cells transfected with the LIFR gene, but not the binding of human OSM to cells transfected with the gp130 gene which is a low-affinity receptor for human OSM (Gearing, unpublished data). We have further confirmed its specificity against the LIFR by using M1 mouse leukemic monocytic cells which express both LIFR and gp130, and terminally differentiate into macrophages when exposed to LIF, OSM or IL-6 (Metcalf et al., 1988; Rose and Bruce, 1991). It has previously been reported that in M1 cells LIFR and gp130 form a bipartite complex and are tyrosine-phosphorylated upon LIF activation, whereas only gp130 is tyrosine-phosphorylated in response to the IL-6 activation (Taga et al., 1992; Davis et al., 1993). Fig. 3A shows the phosphorylation of LIFR (approximately 190 kDa) and gp130 (approximately 145 kDa) in M1 cells treated with LIF.
Role of LIFR in PGC growth

When the same blot was probed with the anti-LIFR serum instead of the anti-phosphotyrosine antibody used in Fig. 3A, only the LIFR protein was seen (Fig. 3B). In addition, the anti-LIFR serum is able to immunologically precipitate tyrosine-phosphorylated LIFR and gp130 in M1 cells treated with LIF (Fig. 3C, lanes 1 and 2), but not tyrosine-phosphorylated gp130 in M1 cells treated with IL-6 (Fig. 3C, lane 3). These data demonstrate that the anti-LIFR serum specifically recognizes the LIFR protein but not the related gp130 protein. However, we cannot rule out the possibility that the anti-LIFR serum can recognize other unidentified receptors that are related LIFR.

We further used this anti-LIFR serum to examine whether the LIFR protein is present on the cell surface of PGCs (Fig. 4). In a two-color FACS analysis, disassociated PGCs were identified by expression of the SSEA-1 antigen and account for about 11% of the total cells isolated from genital ridges. Within the PGC population (SSEA-1+ cells), approximately 50% of the cells stained positive with the LIFR antiserum by comparison with the control serum (Fig. 4). This result demonstrates that the LIFR protein is present on the surface of PGCs and suggests that PGCs are therefore likely to be a direct target of LIF action observed in culture. The LIFR antiserum also stains a population of SSEA-1-negative cells. Since the SSEA-1 antigen is down regulated on the PGC surface after they reach the gonad (Donovan et al., 1986), these cells could represent SSEA-1-negative PGCs. Alternatively these cells could represent gonadal somatic cells that express the LIFR. Macrophages have been identified in the developing urogenital ridge (De Felici et al., 1986) and represent a cell type known to bind I^252-LIF and therefore to express a LIFR receptor (Hilton et al., 1988b).

**Signaling via the LIFR is essential for PGC growth in culture**

Since the anti-LIFR serum blocks LIF binding, we tested its effect on PGC growth in culture. Addition of the LIFR antiserum reduced the number of PGCs in culture in a dose-dependent manner, whereas the control rabbit serum had little effect on PGC growth (Fig. 5A). At higher concentrations the anti-LIFR serum reduced the number of PGCs by more than 75% and did not alter the morphology of feeder cells (data not shown). The blocking effect of the LIFR antiserum observed in these assays is comparable to that of a mAb recognizing the mouse c-kit receptor, ACK-2 (Matsui et al., 1991). Although the addition of exogenous LIF has only a moderate effect on PGC proliferation on STO feeder cells (which produce a suboptimal amount of LIF) (see Fig. 1), the blocking experiment shown here illustrates that signaling via the LIFR protein (or a highly related receptor) is required for PGC growth in culture.

We further tested whether the presence of bFGF could overcome the requirement for LIF and SLF signaling. The addition of bFGF, LIF and SLF at their optimal concentration doubled the number of PGCs in 2 days, consistent with previous results (see Fig. 1). Addition of bFGF did not alleviate the blocking effect of neutralizing antibodies against either the
LIFR or the c-kit receptor (Fig. 5B). The inability of bFGF to bypass the requirement for signaling via the c-kit receptor confirms the conclusion that the SLF/c-kit signal pathway is absolutely required for PGC growth both in vivo and in vitro. Similarly, the data presented here illustrate that signal transduction via the LIFR protein is also essential for PGC growth in vitro.

We also tested the effect on PGC growth of an antibody which specifically recognizes IL-6Rα, the IL-6-binding subunit of the IL-6 receptor. This mAb has been shown to block IL-6 action on several cell lines in vivo and in vitro (Vink et al., 1990), and further tested by us for its effect on IL-6-induced M1 cell growth inhibition and differentiation (see materials and methods). At a concentration of 10 μg per ml, the mAb against IL-6Rα had little effect on PGC growth (Fig. 5B), while it fully blocked M1 cell growth inhibition induced by IL-6 (see Materials and methods). These data suggest that, while signalling via c-kit and LIFR are essential for PGC growth in culture, signalling via the IL-6Rα is not required for their growth.

**Discussion**

Previous studies have demonstrated that LIF can stimulate the proliferation of PGCs cultured on feeder cells. Because LIF
can act on a wide variety of cell types, interpretation of its role in PGC growth is complicated. Here we have demonstrated that LIF can act to stimulate PGC proliferation in the absence of STO feeder cells, suggesting that LIF may act directly on PGCs (Fig. 1). Using a sensitive RNase protection assay, we have also shown that transcripts for the LIF-binding subunit (LIFR) of the high affinity LIF receptor complex are detectable in the developing gonad (Fig. 2). FACs analyses demonstrate that approximately 50% of PGCs (SSEA-1+) cells can be labeled using a specific anti-LIFR antiserum (Fig. 4). Taken together these data demonstrate that PGCs express a LIF receptor and strongly suggest that PGCs are a direct target of LIF action in vitro. We have further shown that the anti-LIFR antiserum completely blocks PGC growth in culture in a manner similar to antibodies to the c-kit receptor tyrosine kinase (Fig. 5). These data suggest that signalling via the LIFR (or a highly related receptor) is required for PGC survival in vitro and may be required for PGC survival in vivo.

It has been proposed that all mammalian cells, excluding blastomeres, may require multiple peptide factors for survival (Raff, 1992). For example, oligodendrocytes require three classes of factors for survival in vivo: (1) insulin and insulin-like growth factors; (2) neurotrophins, particularly neurotrophin-3, and (3) CNTF, LIF or IL-6 (Barres et al., 1993). Whereas a single factor promotes short-term survival, at least one factor from each class is required to promote long-term oligodendrocyte survival in vitro. Some of these survival factors, such as neurotrophin-3, also function as mitogens when cytokines of the other classes are present (Barres et al., 1993). The data presented here suggest that LIF, like SLF, is required for PGC survival in vitro although it seems likely that LIF may also act as a co-mitogen in the presence of other growth factors (Matsui et al., 1991, 1992; Resnick et al., 1992).

The notion that LIF is a PGC survival factor is consistent with data showing that it can suppress programmed cell death (apoptosis) of PGCs in culture (Pesce et al., 1993).

Although we have argued that signalling via the LIFR/gp130 complex is required for PGC survival, mice deficient in LIF are fertile (Stewart et al., 1992; Escary et al., 1993). Three explanations seem plausible. First, animals can have severely reduced numbers of PGCs (SSEA-1+) cells) but still be fertile. For example, animals can have severely reduced numbers of PGCs (SSEA-1+) cells) but still be fertile. For example, when H 17 animals, which have an abnormal SLF cytoplasmic complex is required for PGC survival, mice deficient in LIF (apoptosis) of PGCs in culture (Pesce et al., 1993). LIF may also act as a co-mitogen in the presence of other growth factors (Matsui et al., 1991, 1992; Resnick et al., 1992).

LIF related cytokine may substitute for its function in PGC development. CNTF-deficient animals are also fertile (Masu et al., 1993), but the same arguments apply to these animals as apply to LIF-deficient animals. We are currently trying to determine if one or more these LIFR-dependent cytokines function as a physiological ligand to promote the growth of PGCs in vivo.

The data presented here show that PGCs express a functional LIF receptor composed of LIFR (or a highly related molecule) presumably in association with gp130. These data also argue that activation of this receptor is required for PGC survival. To understand the role of the LIF receptor in PGC development, the temporal and spatial patterns of LIFR and gp130 expression during different stages of PGC development need to be determined. It will be of particular interest to examine LIFR and gp130 expression around 13.5 dpc when PGCs cease mitotic division and undergo differentiation. Activation of the LIFR/gp130 complex has been shown to activate DNA binding of acute-phase response factor (APRF), a transcription factor related to interferon-stimulated gene-factor-3 (ISGF-3α). LIF, OSM and CNTF (as well as IL-6 and IL-11) cause tyrosine phosphorylation of APRF and ISGF-3α as well as inducing kinase activity in the Jak-Tyk family of cytoplasmic tyrosine kinases (Bonni et al., 1993; Lutticken et al., 1994; Stahl et al., 1994). The demonstration that LIF can act directly on PGCs suggests that these proteins may be expressed and activated in PGCs. Understanding the role of this signalling pathway in PGC development may help elucidate both the function and mechanism of action of LIF and related cytokines in PGC development.

We are grateful to Dr James Resnick for his help with RNase protection assays and phosphotyrosine analysis, and for many helpful comments on the manuscript. We thank Dr Douglas Williams (Immunex Corporation, Seattle, Washington) for providing recombinant murine SLF, Dr J.-F. Moreau (CNRS, France) for DA-1a mouse myeloid cells, and Dr Esta Sterneck and Dr Peter F. Johnson (NCI-FCRDC, Frederick, Maryland) for M1 mouse myeloid leukemia cells. We also thank George Smith and Dr Paul Donovan for irradiating STO cells, and John Gooya and Dr Jonathan Keller for assisting in FACs analysis. Research is sponsored in part by the National Cancer Institute, DHHS, under contract N01-C0-74101 with ABL. The contents of this publication do not necessarily reflect the views or policies of the Department of Health and Human Services, nor does the mention of trade names, commercial products, or organizations imply endorsement by the US government.

REFERENCES


(Accepted 12 August 1994)